This comprehensive in silico study intended to identify the potential pyrazole derivatives as the inhibitors/modulators of six attractive therapeutic drug targets (CRMP2, C-RAF, CYP17, c-KIT, VEGFR, and HDAC) for different cancer types that have been extensively studied, including breast, liver, prostate, kidney, and stomach cancers. This evidence concerns the gene DPYSL2 and gastric cancer.